Evidence map›Paper›PMID 38786322›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience.

Kalliopi Andrikou, Paola Ulivi, Elisabetta Petracci, Irene Azzali, Federica Bertolini, Giulia Alberti, Stefania Bettelli, Daniele Calistri, Elisa Chiadini, Laura Capelli and 11 more

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Kalliopi AndrikouMedical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), 47014 Meldola, Italy.
Paola UliviBioscience Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), 47014 Meldola, Italy.
Elisabetta PetracciUnit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
Irene AzzaliUnit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.ORCID 0000-0002-5808-7044
Federica BertoliniOncology Department, Modena University Hospital, 41125 Modena, Italy.
Giulia AlbertiMedical Oncology, IRCCS Arcispedale Santa Maria Nuova, 42123 Reggio Emilia, Italy.ORCID 0000-0003-2616-7477
Stefania BettelliBiomolecular Pathology Unit, Azienda Ospedaliera Unica di Modena, 41125 Modena, Italy.
Daniele CalistriBioscience Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), 47014 Meldola, Italy.ORCID 0000-0002-5064-2023
Elisa ChiadiniBioscience Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), 47014 Meldola, Italy.ORCID 0000-0001-5373-3636
Laura CapelliBioscience Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), 47014 Meldola, Italy.ORCID 0000-0002-6624-7730
Paola CraveroMedical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), 47014 Meldola, Italy.
Giorgia GuaitoliOncology Department, Modena University Hospital, 41125 Modena, Italy.ORCID 0000-0001-8671-9910
Francesca ZanelliMedical Oncology, IRCCS Arcispedale Santa Maria Nuova, 42123 Reggio Emilia, Italy.
Marco Angelo BurgioMedical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), 47014 Meldola, Italy.
Maria PaganoMedical Oncology, IRCCS Arcispedale Santa Maria Nuova, 42123 Reggio Emilia, Italy.
Alberto VerlicchiMedical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), 47014 Meldola, Italy.
Enrica MartinelliOncology Department, Modena University Hospital, 41125 Modena, Italy.ORCID 0009-0003-5386-2827
Katia Di EmidioOncology Department, Modena University Hospital, 41125 Modena, Italy.
Massimo DominiciOncology Department, Modena University Hospital, 41125 Modena, Italy.ORCID 0000-0002-4007-1503
Carmine PintoMedical Oncology, IRCCS Arcispedale Santa Maria Nuova, 42123 Reggio Emilia, Italy.ORCID 0000-0002-3159-5268
Angelo DelmonteMedical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), 47014 Meldola, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The real-world, retrospective, NEROnE registry investigated the impact of next-generation sequencing (NGS) in advanced non-small-cell lung cancer (NSCLC) patients (pts) at three oncology units in the north of Italy between January 2020 and December 2022. We focused on the clinical characterization and outcomes of NSCLC with rare molecular alterations:

Indexed as

inflammatory indexesNSCLConcogene addiction

Identifiers

PMID38786322
PMCPMC11119107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.